Fineline Cube

Follow:
14409 Articles
Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
CompanyDeals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
CompanyDrug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

BeOne Medicines Names Dual Presidents in Leadership Overhaul
Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
CompanyDeals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
CompanyDrug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
CompanyDrug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
CompanyDrug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo
CompanyDrug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
CompanyDeals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
Others

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
CompanyDrug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
CompanyDrug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer